The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer

Tumor Biology

Volumn 28, Issue 6, 2007, Pages 340-349

  Kuemmel, Andreas ^a   Single, Kristjan ^a   Bittinger, Fernando ^a   Faldum, Andrea ^a   Schmidt, Lars Henning ^a   Sebastian, Martin ^a   Taube, Christian ^a   Buhl, Roland ^a   Wiewrodt, Rainer ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

A70 C C8; Blood group antigens; Monoclonal antibody; NSCLC; Overall survival; Time to progression

Indexed keywords

BLOOD GROUP ABH ANTIGEN; BLOOD GROUP ANTIGEN; LEWIS Y ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP LEWIS SYSTEM; CANCER IMMUNOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL;

EID: 42449119626     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000124298     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Bray F, Sankila R, Ferlay J, Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer Clin Oncol 2002;38:99-166.
3. Zhang S, Zhang HS, Cordon-Cardo C, et al: Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int J Cancer 1997;73:50-56.
4. Kristeleit H: IGN-311. Igeneon. Curr Opin Investig Drugs 2005;6:1272-1279.
5. Stahel RA, Lacroix H, Sculier JP, et al: Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. Ann Oncol 1992;3:319-320.
6. Lloyd KO: The chemistry and immunochemistry of blood group A, B, H, and Lewis antigens: past, present and future. Glycoconj J 2000;17:531-541.
7. Garrigues J, Anderson J, Hellstrom KE, Hellstrom I: Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes. J Cell Biol 1994;125:129-142.
8. Yin BW, Finstad CL, Kitamura K, et al: Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer 1996;65:406-412.
9. Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L, Das M: Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. Cancer Res 1987;47:2531-2536.
10. Klinger M, Farhan H, Just H, et al: Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res 2004;64:1087-1093.
11. Kim YS, Yuan M, Itzkowitz SH, et al: Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res 1986;46:5985-5992.
12. Brown A, Ellis IO, Embleton MJ, Baldwin RW, Turner DR, Hardcastle JD: Immunohistochemical localization of Y hapten and the structurally related H type-2 blood-group antigen on large-bowel tumours and normal adult tissues. Int J Cancer 1984;33:727-736.
13. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE: Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990;50:2183-2190.
14. Dettke M, Palfi G, Loibner H: Activation-dependent expression of the blood group-related Lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol 2000;68:511-514.
15. Hiraishi K, Suzuki K, Hakomori S, Adachi M: Le(y) antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993;3:381-390.
16. Abe K, Hakomori S, Ohshiba S: Differential expression of difucosyl type 2 chain (LeY) defined by monoclonal antibody AH6 in different locations of colonic epithelia, various histological types of colonic polyps, and adenocarcinomas. Cancer Res 1986;46:2639-2644.
17. Miyake M, Taki T, Hitomi S, Hakomori S: Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992;327:14-18.
18. Ogawa J, Sano A, Inoue H, Koide S: Expression of Lewis-related antigen and prognosis in stage I non-small cell lung cancer. Ann Thorac Surg 1995;59:412-415.
19. Tanaka F, Miyahara R, Ohtake Y, et al: Lewis Y antigen expression and postoperative survival in non-small cell lung cancer. Ann Thorac Surg 1998;66:1745-1750.
20. Greatens TM, Niehans GA, Rubins JB, et al: Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 1998;157:1093-1097.
21. Christensen PA: The Lewis Y Antigen. Recognition and Mimicry; thesis, Berlin, 2005.
22. Orntoft TF, Wolf H, Clausen H, Dabelsteen E, Hakomori S: Blood group ABH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas. Int J Cancer 1989;43:774-780.
23. Kanters SD, Lammers JW, Voest EE: Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 1995;8:1389-1397.
24. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
25. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC: World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus, ed 1. Lyon, IARC Press, 2004, pp 9-122.
26. Sabattini E, Bisgaard K, Ascani S, et al: The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 1998;51:506-511.
27. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-140.
28. Mehdi SA, Tatum AH, Newman NB, et al: Prognostic significance of Lewis y antigen in resected stage I and II non-small cell lung cancer. Chest 1998;114:1309-1315.
29. Kawai T, Suzuki M, Kase K, Ozeki Y: Expression of carbohydrate antigens in human pulmonary adenocarcinoma. Cancer 1993;72:1581-1587.
30. Aftabuddin M, Yamadori I, Yoshino T, Kondo E, Akagi T: Correlation between the number of apoptotic cells and expression of the apoptosis-related antigens Fas, Le(y) and bcl-2 protein in non-Hodgkin's lymphomas. Pathol Int 1995;45:422-429.
31. Miyake M, Hakomori SI: A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry 1991;30:3328-3334.
32. Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ: Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer. Clin Cancer Res 1997;3:87-93.
33. Lee JS, Ro JY, Sahin AA, et al: Expression of blood-group antigen A - a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 1991;324:1084-1090.
34. Rice TW, Tubbs RR, Hoeltge GA, et al: Expression of blood group antigen A by stage I non-small cell lung carcinomas. Ann Thorac Surg 1995;59:568-572.
35. Moldvay J, Scheid P, Wild P, et al: Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 2000;6:1125-1134.
36. Roberts TE, Hasleton P, Swindell R, Lawson R: Blood groups and lung cancer. Br J Cancer 1988;58:278.
37. Wang W, Rong TH, Zhang L, et al: Multivariate survival analysis for 423 patients with non-small cell lung cancer (in Chinese). Ai Zheng 2003;22:624-628.
38. Cserti CM, Dzik WH: The ABO blood group system and Plasmodium falciparum malaria. Blood 2007;110:2250-2258.
39. Udomsangpetch R, Todd J, Carlson J, Greenwood BM: The effects of hemoglobin genotype and ABO blood group on the formation of rosettes by Plasmodium falciparum-infected red blood cells. Am J Trop Med Hyg 1993;48:149-153.